ACD856 for Health & Longevity - Quick Reference Sheet

ACD856 for Health & Longevity

Created on 09/04/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 Audit

An experimental oral compound that makes brain cells more responsive to their own growth signals. In laboratory work it protected nerve cells and restored memory in old mice. In healthy volunteers it reached the brain and shifted brain-wave patterns, but never improved memory, mood or function in any person. Safety data are thin; all data come from the compound's owner. (Full Review)

Protocol

Studied regimen
10, 30 or 90 mg once daily
Oral solution, seven consecutive days, steady state before day 6. No established protocol; investigational.
Best time of day
Morning
All studies dosed in the morning; peak concentration arrives within 30–45 minutes.
Food
Trials dosed fasted
Food lowered and delayed peak concentration but had little effect on half-life or overall exposure.
Time to effect
Time to effect
Unknown
No cognitive, functional or mood endpoint has ever been measured, so no meaningful time-to-benefit exists.
Brain-wave changes
Within days
Measurable within days of starting. An unvalidated biomarker, not a cognitive outcome.
Half-life
Approximately 20 hours
Steady state reached before day 6 on once-daily dosing; washout within about four days.

Benefits

Contraindications
  • Anyone outside a registered clinical trial
  • History of acute pancreatitis, or baseline lipase or amylase above 3× the upper limit of normal
  • Moderate or severe liver impairment (Child-Pugh Class B or C)
  • Active or previously treated cancer driven by an NTRK gene fusion
  • Women who are pregnant or breastfeeding, and adults under 18
Key Interactions
  • No human interaction study exists
  • Enzyme inhibitors or inducers (ketoconazole, grapefruit juice, rifampicin)
  • Acetylcholinesterase inhibitors (donepezil, rivastigmine)
  • Antidepressants (fluoxetine, ketamine)
  • Anti-nerve-growth-factor antibodies (tanezumab)
  • Pancreatitis-associated drugs (valproate, semaglutide)
  • Sedating antihistamines (diphenhydramine)
  • Pathway-active supplements (7,8-dihydroxyflavone, curcumin, Hericium)
  • Aerobic exercise and sleep extension (potentiating, benign)

Risk & Side Effects

  • Low: Transient pancreatic enzyme elevation; transient liver enzyme elevation; mild to moderate adverse events without a dose relationship.
  • Speculative: Theoretical tumor-promoting potential; increased pain sensitivity; brain-wave slowing of uncertain meaning; mood or behavioral activation.

Monitoring

Marker Target Why
Serum lipase 13–60 U/L The one laboratory signal seen in humans
Serum amylase 30–110 U/L Confirms or refutes a lipase finding
ALT 10–26 U/L (men), 10–19 U/L (women) Clearance is entirely metabolic, so liver stress matters
eGFR ≥90 mL/min/1.73 m² Establishes organ reserve before dosing
Prolactin 3–13 ng/mL (men), 3–20 ng/mL (non-pregnant women) Carried forward from the trial safety panel
Serum brain-derived neurotrophic factor No established target exists; track the change from the individual's own baseline instead Reflects the pathway being amplified

Cadence: Pancreatic and liver enzymes on days 1, 4 and 8, then two weeks after the last dose; questionnaires weekly; brain-wave recording at steady state. A longer outpatient schedule would repeat the panel at 4 and 12 weeks, then every 6–12 months.

Qualitative Assessment

  • Cognitive clarity: word-finding, mental arithmetic under time pressure, and the ease of holding several threads at once, rated weekly on a fixed scale.
  • Memory: recall of the previous day's conversations and reading.
  • Mood and drive: activation, irritability and initiative.
  • Sleep quality: time to fall asleep and number of awakenings.
  • Pain sensitivity: any new or worsened aching or skin tenderness.